Recently, Abbott Diabetes Care posted an alert for a subset of its FreeStyle Libre 3 and Libre 3 Plus continuous glucose monitor (CGM) sensors. Internal testing revealed that some sensors manufactured on a single production line may provide inaccurate, low glucose readings—potentially leading patients to delay or skip necessary insulin doses. The alert affects approximately 3 million sensors in the United States; about half are estimated to have expired or already been used. Globally, Abbott …
Read More
